Orphan nuclear receptor NR4A2 induces transcription of the immunomodulatory peptide hormone prolactin

Journal of Inflammation

Kimberlee S Mix¹  Jordan R Everett¹  Hiba Elaasar¹  Keegan S McCauley¹  Dana E Walkenhorst¹  Joseph M McCoy¹ 

[1] Department of Biological Sciences, Loyola University New Orleans, New Orleans 70118, Louisiana, USA

关键词: Promoter;    Synoviocytes;    Arthritis;    Prolactin;    Transcription;    Orphan nuclear receptor;   

Others  :  1134148
DOI  :  10.1186/s12950-015-0059-2

 received in 2014-06-06, accepted in 2015-01-30,  发布年份 2015

【 摘 要 】

Background

Nuclear receptor 4A2 (NR4A2) is an orphan nuclear receptor and constitutively active transcription factor expressed at elevated levels in inflamed joint tissues from patients with arthritis. Inflammatory mediators rapidly and potently induce NR4A2 expression in resident joint cells and infiltrating immune cells. This receptor promotes synovial hyperplasia by increasing proliferation of synoviocytes and inducing transcription of matrix degrading enzymes and pro-inflammatory mediators. In order to further elucidate the molecular mechanisms of NR4A2, we conducted a gene expression screen to identify novel transcriptional targets of NR4A2 that may contribute to arthritis progression.

Methods

NR4A2 was over-expressed in human synoviocytes by lentiviral transduction and gene expression changes were measured using qPCR arrays specific for inflammation, proliferation, adhesion, and migration pathways. Subsequent analysis focused on the most potently induced gene prolactin (PRL). Messenger RNA levels of PRL and PRL receptor (PRL-R) were measured by RT-qPCR and protein levels were measured by ELISA. PRL promoter studies were conducted in synoviocytes transiently transfected with NR4A2 and PRL reporter constructs. Molecular responses to PRL in synoviocytes were addressed using qPCR arrays specific for JAK/STAT signaling pathways.

Results

PRL was the most potently induced gene on the qPCR arrays, exhibiting a 68-fold increase in response to ectopic NR4A2. This gene encodes an immunomodulatory peptide hormone with roles in autoimmune diseases and inflammation. Induction of PRL mRNA and secreted protein by NR4A2 was confirmed in subsequent experiments, with increases of 300-fold and 18-fold respectively. Depletion of endogenous NR4A receptors with shRNA reduced basal and PGE₂-induced PRL levels by 95%. At the transcriptional level, NR4A2 requires a functional DNA binding domain to transactivate the distal PRL promoter. Deletional analysis indicates that NR4A2 targets a region of the distal PRL promoter spanning −270 to -32 bp. In synoviocytes, recombinant PRL regulates several genes involved in inflammation, proliferation, and cell survival, suggesting that NR4A2 induced PRL may also impact these pathways and contribute to arthritis progression.

Conclusions

These results provide the first evidence for transcriptional regulation of the immunomodulatory peptide hormone PRL by NR4A2 in synoviocytes, and highlight a novel molecular pathway in inflammatory arthritis.

【 授权许可】

   
2015 McCoy et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al.: Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into {SCID} mice. Am J Pathol 1996, 149:1607-15.
• [2]Bartok B, Firestein GS: Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010, 233:233-55.
• [3]Aupperle KR, Boyle DL, Hendrix M, Seftor EA, Zvaifler NJ, Barbosa M, et al.: Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J Pathol 1998, 152:1091-8.
• [4]Li X, Makarov SS: An essential role of {NF-kappaB} in the “tumor-like” phenotype of arthritic synoviocytes. Proc Natl Acad Sci U S A 2006, 103:17432-7.
• [5]Pap T, Nawrath M, Heinrich J, Bosse M, Baier A, Hummel KM, et al.: Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2004, 50:2794-802.
• [6]Takeba Y, Suzuki N, Wakisaka S, Takeno M, Kaneko A, Asai T, et al.: Involvement of {cAMP} responsive element binding protein ({CREB)} in the synovial cell hyperfunction in patients with rheumatoid arthritis. Clin Exp Rheumatol 2000, 18:47-55.
• [7]McEvoy AN, Murphy EA, Ponnio T, Conneely OM, Bresnihan B, FitzGerald O, et al.: Activation of nuclear orphan receptor {NURR1} transcription by {NF-kappa} B and cyclic adenosine 5′-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. J Immunol 2002, 168:2979-87.
• [8]Murphy EP, McEvoy A, Conneely OM, Bresnihan B, FitzGerald O: Involvement of the nuclear orphan receptor {NURR1} in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum 2001, 44:782-93.
• [9]Mix KS, Attur MG, Al-Mussawir H, Abramson SB, Brinckerhoff CE, Murphy EP: Transcriptional repression of matrix metalloproteinase gene expression by the orphan nuclear receptor {NURR1} in cartilage. J Biol Chem 2007, 282:9492-504.
• [10]Mix KS, McMahon K, McMorrow JP, Walkenhorst DE, Smyth AM, Petrella BL, et al.: Orphan nuclear receptor {NR4A2} induces synoviocyte proliferation, invasion, and matrix metalloproteinase 13 transcription. Arthritis Rheum 2012, 64:2126-36.
• [11]Ralph JA, McEvoy AN, Kane D, Bresnihan B, FitzGerald O, Murphy EP: Modulation of orphan nuclear receptor {NURR1} expression by methotrexate in human inflammatory joint disease involves adenosine {A2A} receptor-mediated responses. J Immunol 2005, 175:555-65.
• [12]Ralph JA, Ahmed AU, Santos LL, Clark AR, McMorrow J, Murphy EP, et al.: Identification of {NURR1} as a mediator of {MIF} signaling during chronic arthritis: effects on glucocorticoid-induced {MKP1}. Am J Pathol 2010, 177:2366-78.
• [13]Aherne CM, McMorrow J, Kane D, FitzGerald O, Mix KS, Murphy EP: Identification of {NR4A2} as a transcriptional activator of {IL-8} expression in human inflammatory arthritis. Mol Immunol 2009, 46:3345-57.
• [14]Zhao Y, Bruemmer D: {NR4A} orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol 2010, 30:1535-41.
• [15]Pei L, Castrillo A, Tontonoz P: Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol Endocrinol 2006, 20:786-94.
• [16]Ordentlich P, Yan Y, Zhou S, Heyman RA: Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1. J Biol Chem 2003, 278:24791-9.
• [17]Li X, Lee S-O, Safe S: Structure-dependent activation of NR4A2 (Nurr1) by 1,1-bis (3′-indolyl)-1-(aromatic) methane analogs in pancreatic cancer cells. Biochem Pharmacol 2012, 83(10):1445-55.
• [18]Davies MR, Harding CJ, Raines S, Tolley K, Parker AE, Downey-Jones M, et al.: Nurr1 dependent regulation of pro-inflammatory mediators in immortalised synovial fibroblasts. J Inflamm (Lond) 2005, 2:15. BioMed Central Full Text
• [19]Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C: Prolactin and autoimmunity. Clin Rev Allergy Immunol 2011, 40:50-9.
• [20]Fojtikova M, Tomasova Studynkova J, Filkova M, Lacinova Z, Gatterova J, Pavelka K, et al.: Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage. Clin Exp Rheumatol 2010, 28:849-54.
• [21]Mateo L, Nolla JM, Bonnin MR, Navarro MA, Roig-Escofet D: High serum prolactin levels in men with rheumatoid arthritis. J Rheumatol 1998, 25:2077-82.
• [22]McMurray RW: Bromocriptine in rheumatic and autoimmune diseases. Semin Arthritis Rheum 2001, 31:21-32.
• [23]Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sakane T: Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 1999, 26:1890-900.
• [24]Macotela Y, Aguilar MB, Guzmán-Morales J, Rivera JC, Zermeño C, López-Barrera F, et al.: Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J Cell Sci 2006, 119:1790-800.
• [25]Zermeno C, Guzman-Morales J, Macotela Y, Nava G, Lopez-Barrera F, Kouri JB, et al.: Prolactin inhibits the apoptosis of chondrocytes induced by serum starvation. J Endocrinol 2006, 189:R1-8.
• [26]Ogueta S, Munoz J, Obregon E, Delgado-Baeza E, Garcia-Ruiz JP: Prolactin is a component of the human synovial liquid and modulates the growth and chondrogenic differentiation of bone marrow-derived mesenchymal stem cells. Mol Cell Endocrinol 2002, 190:51-63.
• [27]Adán N, Guzmán-Morales J, Ledesma-Colunga MG, Perales-Canales SI, Quintanar-Stéphano A, López-Barrera F, et al.: Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. J Clin Invest 2013, 123:3902-13.
• [28]Haas C, Aicher WK, Dinkel A, Peter HH, Eibel H: Characterization of {SV40T} antigen immortalized human synovial fibroblasts: maintained expression patterns of {EGR-1}, {HLA-DR} and some surface receptors. Rheumatol Int 1997, 16:241-7.
• [29]Ben-Batalla I, Seoane S, Macia M, Garcia-Caballero T, Gonzalez LO, Vizoso F, et al.: The Pit-{1/Pou1f1} transcription factor regulates and correlates with prolactin expression in human breast cell lines and tumors. Endocr Relat Cancer 2010, 17:73-85.
• [30]Christian M, Pohnke Y, Kempf R, Gellersen B, Brosens JJ: Functional association of PR and CCAAT/enhancer-binding protein beta isoforms: promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells. Mol Endocrinol 2002, 16:141-54.
• [31]Pohnke Y, Kempf R, Gellersen B: {CCAAT/enhancer-binding} proteins are mediators in the protein kinase A-dependent activation of the decidual prolactin promoter. J Biol Chem 1999, 274:24808-18.
• [32]Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, et al.: Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003, 62:100-7.
• [33]Tardif G, Hum D, Pelletier J-P, Boileau C, Ranger P, Martel-Pelletier J: Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum 2004, 50:2521-30.
• [34]Berwaer M, Martial JA, Davis JR: Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. Mol Endocrinol 1994, 8:635-42.
• [35]Gellersen B, DiMattia GE, Friesen HG, Bohnet HG: Prolactin ({PRL)} {mRNA} from human decidua differs from pituitary {PRL} {mRNA} but resembles the {IM-9-P3} lymphoblast {PRL} transcript. Mol Cell Endocrinol 1989, 64:127-30.
• [36]Creamer BA, Sakamoto K, Schmidt JW, Triplett AA, Moriggl R, Wagner K-U: Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. Mol Cell Biol 2010, 30:2957-70.
• [37]Yu-Lee LY: Prolactin stimulates transcription of growth-related genes in Nb2 T lymphoma cells. Mol Cell Endocrinol 1990, 68:21-8.
• [38]Motta M, Accornero P, Baratta M: Leptin and prolactin modulate the expression of SOCS-1 in association with interleukin-6 and tumor necrosis factor-alpha in mammary cells: a role in differentiated secretory epithelium. Regul Pept 2004, 121:163-70.
• [39]Morel J, Audo R, Hahne M, Combe B: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005, 280:15709-18.
• [40]Chen Q, Casali B, Pattacini L, Boiardi L, Salvarani C: Tumor necrosis factor-alpha protects synovial cells from nitric oxide induced apoptosis through phosphoinositide 3-kinase Akt signal transduction. J Rheumatol 2006, 33:1061-8.
• [41]Woods JM, Klosowska K, Spoden DJ, Stumbo NG, Paige DJ, Scatizzi JC, et al.: A cell-cycle independent role for p21 in regulating synovial fibroblast migration in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R113. BioMed Central Full Text
• [42]Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, Sugita Y, et al.: Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol 2012, 41(3):170-79.
• [43]Nishioka K, Ohshima S, Umeshita-Sasai M, Yamaguchi N, Mima T, Nomura S, et al.: Enhanced expression and DNA binding activity of two CCAAT/enhancer-binding protein isoforms, C/EBPbeta and C/EBPdelta, in rheumatoid synovium. Arthritis Rheum 2000, 43:1591-6.
• [44]Gerlo S, Verdood P, Gellersen B, Hooghe-Peters EL, Kooijman R: Mechanism of prostaglandin ({PG) E2-induced} prolactin expression in human T cells: cooperation of two {PGE2} receptor subtypes, E-prostanoid ({EP)} 3 and {EP4}, via calcium- and cyclic adenosine 5′-monophosphate-mediated signaling pathways. J Immunol 2004, 173:5952-62.
• [45]Reem GH, Ray DW, Davis JR: The human prolactin gene upstream promoter is regulated in lymphoid cells by activators of T-cells and by {cAMP}. J Mol Endocrinol 1999, 22:285-92.
• [46]Gellersen B, Kempf R, Telgmann R, DiMattia GE: Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol Endocrinol 1994, 8:356-73.
• [47]Jiang Y, Hu Y, Zhao J, Zhen X, Yan G, Sun H: The orphan nuclear receptor Nur77 regulates decidual prolactin expression in human endometrial stromal cells. Biochem Biophys Res Commun 2011, 404:628-33.
• [48]Lynch VJ, Brayer K, Gellersen B, Wagner GP: HoxA-11 and FOXO1A cooperate to regulate decidual prolactin expression: towards inferring the core transcriptional regulators of decidual genes. PLoS One 2009, 4:e6845.
• [49]Brar AK, Kessler CA, Handwerger S: An Ets motif in the proximal decidual prolactin promoter is essential for basal gene expression. J Mol Endocrinol 2002, 29:99-112.
• [50]Reuwer AQ, Nowak-Sliwinska P, Mans LA, van der Loos CM, von der Thusen JH, Twickler MT, et al.: Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology? J Cell Mol Med 2012, 16:2035-48.
• [51]Struman I, Bentzien F, Lee H, Mainfroid V, D’Angelo G, Goffin V, et al.: Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A 1999, 96:1246-51.